Form 4 for IMMX Immix Biopharma, Inc.
Accepted 2023-09-14 00:00:00 ET · period of report 2023-09-12 · accession 0001493152-23-032664 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-09-14 | 2023-09-12 | IMMX | Adams Helen C. | Dir | P - Purchase | $2.96 | +13.0K | 13.0K | New | +$38.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-09-12 | P | A | 13,000 | $2.96 | 13,000 | D | — | — | (F1) This figure is the weighted average sales price of multiple trades ranging from $2.90 to $3.25 per share. The Reporting Person undertakes to provide the staff of the Securities and Exchange Commission, Immix Biopharma, Inc. or any security holder of Immix Biopharma, Inc. full information about the number of shares sold at each separate price upon request. |